Cargando…
Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts
BACKGROUND: Polo-like kinase 4 PLK4 plays a key role in centriole replication. Hence PLK4 inhibition disrupts mitosis, and offers a novel approach to treating chromosomally unstable cancers, including pancreatic cancer. CFI-400945 is a first in class small molecule PLK4 inhibitor, currently undergoi...
Autores principales: | Lohse, Ines, Mason, Jacqueline, Mary, Pinjiang Cao, Pintilie, Melania, Bray, Mark, Hedley, David W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356865/ https://www.ncbi.nlm.nih.gov/pubmed/27902970 http://dx.doi.org/10.18632/oncotarget.13619 |
Ejemplares similares
-
Polo-like kinase 4 inhibitor CFI-400945 inhibits carotid arterial neointima formation but increases atherosclerosis
por: Sun, Jiaxing, et al.
Publicado: (2023) -
Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer
por: Parsyan, Armen, et al.
Publicado: (2021) -
Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells
por: Kerschner-Morales, Sophie L., et al.
Publicado: (2020) -
Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302
por: Lohse, Ines, et al.
Publicado: (2016) -
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial
por: Veitch, Zachary W., et al.
Publicado: (2019)